Clinical Trials Logo

SARS Coronavirus 2 Infection clinical trials

View clinical trials related to SARS Coronavirus 2 Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT04778059 Terminated - Clinical trials for SARS-CoV-2 Infection

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

Start date: July 27, 2021
Phase: Phase 2
Study type: Interventional

This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.

NCT ID: NCT04361552 Withdrawn - Clinical trials for Coronary Artery Disease

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Start date: April 7, 2020
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.